Herting, F., Friess, T., Bader, S., Muth, G., Hölzlwimmer, G., Rieder, N., . . . Klein, C. (2014). Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Informa Healthcare.
Citação norma ChicagoHerting, Frank, Thomas Friess, Sabine Bader, Gunter Muth, Gabriele Hölzlwimmer, Natascha Rieder, Pablo Umana, and Christian Klein. Enhanced Anti-tumor Activity of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) in Combination With Chemotherapy in Xenograft Models of Human Lymphoma. Informa Healthcare, 2014.
Citação norma MLAHerting, Frank, et al. Enhanced Anti-tumor Activity of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) in Combination With Chemotherapy in Xenograft Models of Human Lymphoma. Informa Healthcare, 2014.